Article Correctness Is Author's Responsibility: Addition of sintilimab to pemetrexed and platinum improved progression-free survival

(International Association for the Study of Lung Cancer) The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.